Member Login
  1. Stocks
    2. /
  2. Indivior PLC (LSE: INDV)
    3. /

LSE:INDV (Indivior PLC)

About INDV

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Indivior PLC (LSE: INDV) Latest News

    Investing Articles

    The Indivior share price is smashing the FTSE 250. Should I buy now?

    | Alan Oscroft

    The Indivior share price has been leading the FTSE 250 for days, on the back of great 2020 results. I'm…

    Read more »

    Investing Articles

    Indivior is the biggest FTSE 250 gainer today. Would I buy it now?

    | Manika Premsingh

    The Indivior share price is up after it posted a surprisingly good financial update. Is it a buy now?

    Read more »

    Investing Articles

    Why the Indivior share price crashed 30% today. And what I’d do now

    | Manika Premsingh

    FTSE 250 stock Indivior fell dramatically today after its former parent company Reckitt Benckiser slapped a claim on it. What…

    Read more »

    Investing Articles

    Why did the Indivior share price crash 40% on Friday?

    | Alan Oscroft

    The Indivior share price has just slumped, but it has still more than doubled in 2020. I take a look…

    Read more »

    Investing Articles

    Is the Abcam share price too expensive?

    | Kirsteen Mackay

    The Abcam share price is volatile as speculation keeps it in the news. Has it got the potential to soar…

    Read more »

    Investing Articles

    Top shares for December 2019

    | The Motley Fool Staff

    We asked our freelance writers to share their top stock picks for the month.

    Read more »

    Investing Articles

    Forget the cash ISA! I’d buy this FTSE 100 dividend bargain today

    | Rupert Hargreaves

    This former FTSE 100 (INDEXFTSE: UKX) darling has fallen on hard times, but this could be the perfect opportunity for…

    Read more »

    Investing Articles

    Is the Reckitt Benckiser share price finally low enough to make the stock a bargain for me?

    | Manika Premsingh

    I think there’s a strong case to buy shares of Reckitt Benckiser Group plc (LON: RB) with good growth prospects,…

    Read more »

    Investing Articles

    Is it game over for pharma flop Indivior after 75% crash?

    | Roland Head

    What's gone wrong at Indivior plc (LON:INDV) and what would I do now? Roland Head gives his verdict.

    Read more »

    Investing Articles

    An 8% FTSE 100 dividend stock I’d buy today, and a falling knife I’d avoid

    | Roland Head

    This 8% FTSE 100 (INDEXFTSE:UKX) dividend stock looks reasonably priced, says Roland Head.

    Read more »

    Investing Articles

    Could this year’s biggest FTSE 250 fallers be 2019’s biggest winners?

    | G A Chester

    These FTSE 250 (INDEXFTSE:MCX) stocks have fallen 65% or more. Is it time to load up for 2019?

    Read more »

    Investing Articles

    Forget 1.5% from a cash ISA. FTSE 100 member AstraZeneca is up by 20% in 2018

    | Roland Head

    Roland Head asks whether FTSE 100 (INDEXFTSE:UKX) dividend stock AstraZeneca plc (LON:AZN) deserves a buy rating.

    Read more »